Cargando…

Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population

BACKGROUND: The association of recombinant FSH (rFSH) plus recombinant LH (rLH) is currently used for Controlled Ovarian Stimulation (COS) in human IVF, but its efficacy has, to date, not yet been compared to that of human Menopausal Gonadotropin (hMG), the FSH + LH activity-containing urinary drug....

Descripción completa

Detalles Bibliográficos
Autores principales: Revelli, Alberto, Pettinau, Grazia, Basso, Gemma, Carosso, Andrea, Ferrero, Alessandro, Dallan, Cecilia, Canosa, Stefano, Gennarelli, Gianluca, Guidetti, Daniela, Filippini, Claudia, Benedetto, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514947/
https://www.ncbi.nlm.nih.gov/pubmed/26209525
http://dx.doi.org/10.1186/s12958-015-0080-6
_version_ 1782382843244052480
author Revelli, Alberto
Pettinau, Grazia
Basso, Gemma
Carosso, Andrea
Ferrero, Alessandro
Dallan, Cecilia
Canosa, Stefano
Gennarelli, Gianluca
Guidetti, Daniela
Filippini, Claudia
Benedetto, Chiara
author_facet Revelli, Alberto
Pettinau, Grazia
Basso, Gemma
Carosso, Andrea
Ferrero, Alessandro
Dallan, Cecilia
Canosa, Stefano
Gennarelli, Gianluca
Guidetti, Daniela
Filippini, Claudia
Benedetto, Chiara
author_sort Revelli, Alberto
collection PubMed
description BACKGROUND: The association of recombinant FSH (rFSH) plus recombinant LH (rLH) is currently used for Controlled Ovarian Stimulation (COS) in human IVF, but its efficacy has, to date, not yet been compared to that of human Menopausal Gonadotropin (hMG), the FSH + LH activity-containing urinary drug. METHODS: Eight hundred forty-eight (848) IVF patients classified as expected “poor” or “normal” responders according to antral follicle count (AFC) and basal (day 3) FSH were treated with rFSH + rLH (2:1 ratio, n = 398, Group A) or hMG (n = 450, Group B). Data were collected under real-life practice circumstances and the pregnancy rate with fresh embryos was calculated by stratifying patients according to the number of retrieved oocytes (1–2, 3–4, 5–6, 7–8, >8). RESULTS: Overall, the pregnancy rate in both groups progressively improved according to the number of oocytes retrieved. When comparing patients within the same subgroup of oocyte yield, Group A and B showed a comparable outcome up to the reported highest yield (>8). When more than 8 oocytes were available, Group A had a significantly better pregnancy rate outcome. Patients’ characteristics did not significantly differ between the two groups and the better outcome in the best responding patients in Group A was confirmed by a multivariable logistic regression analysis, that showed that both the use of rFSH + rLH and the total number of retrieved oocytes increased the probability of pregnancy with odd ratio (OR) of 1.628 and 1.083, respectively. CONCLUSIONS: When comparing patients with the same number of retrieved oocytes under real-life circumstances, the association of rFSH + rLH results in a significantly higher pregnancy rate than hMG when more than 8 oocytes are retrieved. The reason(s) for this are unknown, but a more favorable effect on oocyte quality and/or endometrial receptivity could be involved.
format Online
Article
Text
id pubmed-4514947
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45149472015-07-26 Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population Revelli, Alberto Pettinau, Grazia Basso, Gemma Carosso, Andrea Ferrero, Alessandro Dallan, Cecilia Canosa, Stefano Gennarelli, Gianluca Guidetti, Daniela Filippini, Claudia Benedetto, Chiara Reprod Biol Endocrinol Research BACKGROUND: The association of recombinant FSH (rFSH) plus recombinant LH (rLH) is currently used for Controlled Ovarian Stimulation (COS) in human IVF, but its efficacy has, to date, not yet been compared to that of human Menopausal Gonadotropin (hMG), the FSH + LH activity-containing urinary drug. METHODS: Eight hundred forty-eight (848) IVF patients classified as expected “poor” or “normal” responders according to antral follicle count (AFC) and basal (day 3) FSH were treated with rFSH + rLH (2:1 ratio, n = 398, Group A) or hMG (n = 450, Group B). Data were collected under real-life practice circumstances and the pregnancy rate with fresh embryos was calculated by stratifying patients according to the number of retrieved oocytes (1–2, 3–4, 5–6, 7–8, >8). RESULTS: Overall, the pregnancy rate in both groups progressively improved according to the number of oocytes retrieved. When comparing patients within the same subgroup of oocyte yield, Group A and B showed a comparable outcome up to the reported highest yield (>8). When more than 8 oocytes were available, Group A had a significantly better pregnancy rate outcome. Patients’ characteristics did not significantly differ between the two groups and the better outcome in the best responding patients in Group A was confirmed by a multivariable logistic regression analysis, that showed that both the use of rFSH + rLH and the total number of retrieved oocytes increased the probability of pregnancy with odd ratio (OR) of 1.628 and 1.083, respectively. CONCLUSIONS: When comparing patients with the same number of retrieved oocytes under real-life circumstances, the association of rFSH + rLH results in a significantly higher pregnancy rate than hMG when more than 8 oocytes are retrieved. The reason(s) for this are unknown, but a more favorable effect on oocyte quality and/or endometrial receptivity could be involved. BioMed Central 2015-07-25 /pmc/articles/PMC4514947/ /pubmed/26209525 http://dx.doi.org/10.1186/s12958-015-0080-6 Text en © Revelli et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Revelli, Alberto
Pettinau, Grazia
Basso, Gemma
Carosso, Andrea
Ferrero, Alessandro
Dallan, Cecilia
Canosa, Stefano
Gennarelli, Gianluca
Guidetti, Daniela
Filippini, Claudia
Benedetto, Chiara
Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population
title Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population
title_full Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population
title_fullStr Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population
title_full_unstemmed Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population
title_short Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population
title_sort controlled ovarian stimulation with recombinant-fsh plus recombinant-lh vs. human menopausal gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514947/
https://www.ncbi.nlm.nih.gov/pubmed/26209525
http://dx.doi.org/10.1186/s12958-015-0080-6
work_keys_str_mv AT revellialberto controlledovarianstimulationwithrecombinantfshplusrecombinantlhvshumanmenopausalgonadotropinbasedonthenumberofretrievedoocytesresultsfromaroutineclinicalpracticeinareallifepopulation
AT pettinaugrazia controlledovarianstimulationwithrecombinantfshplusrecombinantlhvshumanmenopausalgonadotropinbasedonthenumberofretrievedoocytesresultsfromaroutineclinicalpracticeinareallifepopulation
AT bassogemma controlledovarianstimulationwithrecombinantfshplusrecombinantlhvshumanmenopausalgonadotropinbasedonthenumberofretrievedoocytesresultsfromaroutineclinicalpracticeinareallifepopulation
AT carossoandrea controlledovarianstimulationwithrecombinantfshplusrecombinantlhvshumanmenopausalgonadotropinbasedonthenumberofretrievedoocytesresultsfromaroutineclinicalpracticeinareallifepopulation
AT ferreroalessandro controlledovarianstimulationwithrecombinantfshplusrecombinantlhvshumanmenopausalgonadotropinbasedonthenumberofretrievedoocytesresultsfromaroutineclinicalpracticeinareallifepopulation
AT dallancecilia controlledovarianstimulationwithrecombinantfshplusrecombinantlhvshumanmenopausalgonadotropinbasedonthenumberofretrievedoocytesresultsfromaroutineclinicalpracticeinareallifepopulation
AT canosastefano controlledovarianstimulationwithrecombinantfshplusrecombinantlhvshumanmenopausalgonadotropinbasedonthenumberofretrievedoocytesresultsfromaroutineclinicalpracticeinareallifepopulation
AT gennarelligianluca controlledovarianstimulationwithrecombinantfshplusrecombinantlhvshumanmenopausalgonadotropinbasedonthenumberofretrievedoocytesresultsfromaroutineclinicalpracticeinareallifepopulation
AT guidettidaniela controlledovarianstimulationwithrecombinantfshplusrecombinantlhvshumanmenopausalgonadotropinbasedonthenumberofretrievedoocytesresultsfromaroutineclinicalpracticeinareallifepopulation
AT filippiniclaudia controlledovarianstimulationwithrecombinantfshplusrecombinantlhvshumanmenopausalgonadotropinbasedonthenumberofretrievedoocytesresultsfromaroutineclinicalpracticeinareallifepopulation
AT benedettochiara controlledovarianstimulationwithrecombinantfshplusrecombinantlhvshumanmenopausalgonadotropinbasedonthenumberofretrievedoocytesresultsfromaroutineclinicalpracticeinareallifepopulation